DELCATH SYSTEMS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Delcath reported Q2 2026 revenue of $29.1M (vs. $24.2M in Q2 2025), with HEPZATO KIT sales of $27.1M (vs. $22.5M YoY), representing ~30% volume growth. The company raised full-year 2026 revenue guidance to $104–108M range, reflecting ≥28% HEPZATO volume growth over 2025, with gross margins of 86–89% and positive adjusted EBITDA. Cash and investments stood at $95.9M with zero debt; 31 active treatment centers are now operational.
Why this rating
Strong 20% revenue growth, margin improvement (90% vs. 86% YoY), and raised guidance signal execution momentum. At ~$419.7M market cap, a $104–108M annual revenue run is meaningful scale. Clinical expansion into new indications and 31 treatment centers show durable growth, though adjusted EBITDA declined YoY.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.